SHANGHAI, China & NEW YORK, July 20, 2026
Argo Biopharma has announced the successful dosing of the first participant in the Phase I clinical trial evaluating BW-41012, an investigational small interfering RNA (siRNA) therapy targeting Factor XI (FXI) for the prevention of thromboembolic diseases. The milestone represents another significant advancement for the company’s expanding RNA interference (RNAi) therapeutic pipeline and marks the eighth clinical-stage candidate developed by Argo Biopharma. In parallel with initiating the first-in-human study, the company also received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA), further accelerating the global clinical development of BW-41012. Designed to offer effective protection against blood clot formation while potentially reducing the bleeding risks associated with conventional anticoagulants, BW-41012 reflects the growing promise of RNAi technology in cardiovascular medicine and precision therapeutics. The combined clinical and regulatory achievements strengthen Argo Biopharma’s position as a leading innovator developing next-generation RNA-based medicines for serious cardiovascular disorders.
BW-41012 Advances Novel RNAi Strategy for Thromboembolic Diseases
BW-41012 is an innovative siRNA therapeutic specifically designed to silence Factor XI (FXI) messenger RNA, reducing production of the coagulation factor responsible for blood clot formation. FXI inhibition has emerged as one of the most promising approaches in anticoagulation because it aims to prevent thrombosis while minimizing the bleeding complications frequently associated with existing anticoagulant therapies. The ongoing Phase I clinical trial is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study being conducted in healthy volunteers in Australia. Researchers will evaluate the therapy’s safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and biological activity following subcutaneous administration. Key endpoints include monitoring FXI activity, FXI antigen levels, electrocardiogram (ECG) findings, clinical laboratory parameters, and vital signs, generating critical data to support future clinical development for multiple thromboembolic conditions.
Global Development Targets High-Unmet Cardiovascular Needs
Thromboembolic diseases remain a leading cause of morbidity and mortality worldwide, encompassing serious conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), ischemic stroke, and other thrombotic disorders. While current anticoagulant medications have significantly improved patient outcomes, their widespread use continues to be limited by an increased risk of major bleeding. By targeting Factor XI, BW-41012 seeks to deliver an improved therapeutic balance between effective clot prevention and enhanced safety, potentially addressing one of the most significant unmet needs in cardiovascular medicine. The recent NMPA IND approval complements the initiation of the Australian Phase I study, demonstrating Argo Biopharma’s commitment to advancing a coordinated global clinical development program that supports regulatory expansion across multiple international markets. Positive early-stage results could position BW-41012 among the emerging class of next-generation anticoagulants being developed through advanced RNA interference technologies.
Advertisement
Argo Biopharma Expands Leadership in RNAi Therapeutics
The launch of the BW-41012 clinical trial further reinforces Argo Biopharma’s growing leadership in RNAi drug development. As a clinical-stage biotechnology company, Argo has established a diversified portfolio of eight RNAi candidates spanning cardiovascular diseases, viral infections, metabolic disorders, and rare diseases. The company’s strategy focuses on leveraging the precision and durability of small interfering RNA therapeutics to selectively silence disease-causing genes while improving treatment effectiveness and patient safety. The successful dosing of the first participant, combined with regulatory progress in China, highlights the continued momentum of Argo’s clinical pipeline and its commitment to advancing innovative therapies that address critical unmet medical needs. As RNAi technology continues to reshape the future of precision medicine, BW-41012 has the potential to become an important therapeutic option for preventing thromboembolic diseases, supporting safer anticoagulation strategies, and expanding the clinical impact of gene-silencing medicines worldwide.
Source: Argo Biopharma press release
